The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis

Tripartite motif 8 (TRIM8), an E3 ligase ubiquitously expressed in various cells, is closely involved in innate immunity. However, its role in nonalcoholic steatohepatitis is largely unknown. Here, we report evidence that TRIM8 is a robust enhancer of steatohepatitis and its complications induced by...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology (Baltimore, Md.) Md.), 2017-05, Vol.65 (5), p.1492-1511
Hauptverfasser: Yan, Feng‐Juan, Zhang, Xiao‐Jing, Wang, Wen‐Xin, Ji, Yan‐Xiao, Wang, Pi‐Xiao, Yang, Yang, Gong, Jun, Shen, Li‐Jun, Zhu, Xue‐Yong, Huang, Zan, Li, Hongliang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1511
container_issue 5
container_start_page 1492
container_title Hepatology (Baltimore, Md.)
container_volume 65
creator Yan, Feng‐Juan
Zhang, Xiao‐Jing
Wang, Wen‐Xin
Ji, Yan‐Xiao
Wang, Pi‐Xiao
Yang, Yang
Gong, Jun
Shen, Li‐Jun
Zhu, Xue‐Yong
Huang, Zan
Li, Hongliang
description Tripartite motif 8 (TRIM8), an E3 ligase ubiquitously expressed in various cells, is closely involved in innate immunity. However, its role in nonalcoholic steatohepatitis is largely unknown. Here, we report evidence that TRIM8 is a robust enhancer of steatohepatitis and its complications induced by a high‐fat diet or a genetic deficiency (ob/ob). Using gain‐of‐function and loss‐of‐function approaches, we observed dramatic exacerbation of insulin resistance, hepatic steatosis, inflammation, and fibrosis by hepatocyte‐specific TRIM8 overexpression, whereas deletion or down‐regulation of TRIM8 in hepatocytes led to a completely opposite phenotype. Furthermore, investigations of the underlying mechanisms revealed that TRIM8 directly binds to and ubiquitinates transforming growth factor‐beta–activated kinase 1, thus promoting its phosphorylation and the activation of downstream c‐Jun N‐terminal kinase/p38 and nuclear factor κB signaling. Importantly, the participation of TRIM8 in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis was verified on the basis of its dramatically increased expression in the livers of these patients, suggesting a promising development of TRIM8 disturbance for the treatment of nonalcoholic steatohepatitis–related metabolic disorders. Conclusion: The E3 ligase TRIM8 is a potent regulator that exacerbates steatohepatitis and metabolic disorders dependent on its binding and ubiquitinating capacity on transforming growth factor‐beta–activated kinase 1. (Hepatology 2017;65:1492‐1511)
doi_str_mv 10.1002/hep.28971
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1897375821</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1897375821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4141-aa2f684bdf405f33cb10ba27c863b1f4bf4703e45750e97c326af879eba6e71b3</originalsourceid><addsrcrecordid>eNqN0T1vFDEQBmALgcgRKPgDyBINFJuMv-0yig6CEgmKo7a8e-PE0d7uYXuF8u9xcoECiYjKxTx6NZ6XkLcMThgAP73B_Qm3zrBnZMUUN50QCp6TFXADnWPCHZFXpdwCgJPcviRH3DjLNLgV8ZsbpGtBx3QdCtKa0z7kmirS3VxTpJbWkK-xFro5u2S0znSf5zZCmqayjGmiGUsqNUwD0jBtaakY6tw2Ci0lldfkRQxjwTeP7zH5_mm9Ob_orr5-_nJ-dtUNkknWhcCjtrLfRgkqCjH0DPrAzWC16FmUfZQGBEplFKAzg-A6RGsc9kGjYb04Jh8OuW29HwuW6nepDDiOYcJ5KZ618wijLGf_QRXXVnMrGn3_F72dlzy1j3jmQIDWzugnlbVOcemUbOrjQQ15LiVj9PucdiHfeQb-vkbfjuYfamz23WPi0u9w-0f-7q2B0wP4mUa8-3eSv1h_O0T-AknxpKw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1889524954</pqid></control><display><type>article</type><title>The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Yan, Feng‐Juan ; Zhang, Xiao‐Jing ; Wang, Wen‐Xin ; Ji, Yan‐Xiao ; Wang, Pi‐Xiao ; Yang, Yang ; Gong, Jun ; Shen, Li‐Jun ; Zhu, Xue‐Yong ; Huang, Zan ; Li, Hongliang</creator><creatorcontrib>Yan, Feng‐Juan ; Zhang, Xiao‐Jing ; Wang, Wen‐Xin ; Ji, Yan‐Xiao ; Wang, Pi‐Xiao ; Yang, Yang ; Gong, Jun ; Shen, Li‐Jun ; Zhu, Xue‐Yong ; Huang, Zan ; Li, Hongliang</creatorcontrib><description>Tripartite motif 8 (TRIM8), an E3 ligase ubiquitously expressed in various cells, is closely involved in innate immunity. However, its role in nonalcoholic steatohepatitis is largely unknown. Here, we report evidence that TRIM8 is a robust enhancer of steatohepatitis and its complications induced by a high‐fat diet or a genetic deficiency (ob/ob). Using gain‐of‐function and loss‐of‐function approaches, we observed dramatic exacerbation of insulin resistance, hepatic steatosis, inflammation, and fibrosis by hepatocyte‐specific TRIM8 overexpression, whereas deletion or down‐regulation of TRIM8 in hepatocytes led to a completely opposite phenotype. Furthermore, investigations of the underlying mechanisms revealed that TRIM8 directly binds to and ubiquitinates transforming growth factor‐beta–activated kinase 1, thus promoting its phosphorylation and the activation of downstream c‐Jun N‐terminal kinase/p38 and nuclear factor κB signaling. Importantly, the participation of TRIM8 in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis was verified on the basis of its dramatically increased expression in the livers of these patients, suggesting a promising development of TRIM8 disturbance for the treatment of nonalcoholic steatohepatitis–related metabolic disorders. Conclusion: The E3 ligase TRIM8 is a potent regulator that exacerbates steatohepatitis and metabolic disorders dependent on its binding and ubiquitinating capacity on transforming growth factor‐beta–activated kinase 1. (Hepatology 2017;65:1492‐1511)</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.28971</identifier><identifier>PMID: 27981609</identifier><identifier>CODEN: HPTLD9</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Animals ; c-Jun protein ; Carrier Proteins - metabolism ; Clonal deletion ; Diet, High-Fat ; Fatty liver ; Fatty Liver - enzymology ; Fibrosis ; Growth factors ; Hepatocytes ; Hepatology ; High fat diet ; Humans ; Innate immunity ; Insulin ; Insulin Resistance ; JNK protein ; Lipid Metabolism ; Liver - metabolism ; Liver - pathology ; Liver diseases ; Male ; MAP Kinase Kinase Kinases - metabolism ; MAP Kinase Signaling System ; Metabolic disorders ; Mice, Transgenic ; Nerve Tissue Proteins - metabolism ; Phosphorylation ; Steatosis ; TAK1 protein ; Transcription factors ; Ubiquitin-protein ligase ; Ubiquitination</subject><ispartof>Hepatology (Baltimore, Md.), 2017-05, Vol.65 (5), p.1492-1511</ispartof><rights>2016 by the American Association for the Study of Liver Diseases.</rights><rights>2017 by the American Association for the Study of Liver Diseases.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4141-aa2f684bdf405f33cb10ba27c863b1f4bf4703e45750e97c326af879eba6e71b3</citedby><cites>FETCH-LOGICAL-c4141-aa2f684bdf405f33cb10ba27c863b1f4bf4703e45750e97c326af879eba6e71b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.28971$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.28971$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27981609$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yan, Feng‐Juan</creatorcontrib><creatorcontrib>Zhang, Xiao‐Jing</creatorcontrib><creatorcontrib>Wang, Wen‐Xin</creatorcontrib><creatorcontrib>Ji, Yan‐Xiao</creatorcontrib><creatorcontrib>Wang, Pi‐Xiao</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Gong, Jun</creatorcontrib><creatorcontrib>Shen, Li‐Jun</creatorcontrib><creatorcontrib>Zhu, Xue‐Yong</creatorcontrib><creatorcontrib>Huang, Zan</creatorcontrib><creatorcontrib>Li, Hongliang</creatorcontrib><title>The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>Tripartite motif 8 (TRIM8), an E3 ligase ubiquitously expressed in various cells, is closely involved in innate immunity. However, its role in nonalcoholic steatohepatitis is largely unknown. Here, we report evidence that TRIM8 is a robust enhancer of steatohepatitis and its complications induced by a high‐fat diet or a genetic deficiency (ob/ob). Using gain‐of‐function and loss‐of‐function approaches, we observed dramatic exacerbation of insulin resistance, hepatic steatosis, inflammation, and fibrosis by hepatocyte‐specific TRIM8 overexpression, whereas deletion or down‐regulation of TRIM8 in hepatocytes led to a completely opposite phenotype. Furthermore, investigations of the underlying mechanisms revealed that TRIM8 directly binds to and ubiquitinates transforming growth factor‐beta–activated kinase 1, thus promoting its phosphorylation and the activation of downstream c‐Jun N‐terminal kinase/p38 and nuclear factor κB signaling. Importantly, the participation of TRIM8 in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis was verified on the basis of its dramatically increased expression in the livers of these patients, suggesting a promising development of TRIM8 disturbance for the treatment of nonalcoholic steatohepatitis–related metabolic disorders. Conclusion: The E3 ligase TRIM8 is a potent regulator that exacerbates steatohepatitis and metabolic disorders dependent on its binding and ubiquitinating capacity on transforming growth factor‐beta–activated kinase 1. (Hepatology 2017;65:1492‐1511)</description><subject>Animals</subject><subject>c-Jun protein</subject><subject>Carrier Proteins - metabolism</subject><subject>Clonal deletion</subject><subject>Diet, High-Fat</subject><subject>Fatty liver</subject><subject>Fatty Liver - enzymology</subject><subject>Fibrosis</subject><subject>Growth factors</subject><subject>Hepatocytes</subject><subject>Hepatology</subject><subject>High fat diet</subject><subject>Humans</subject><subject>Innate immunity</subject><subject>Insulin</subject><subject>Insulin Resistance</subject><subject>JNK protein</subject><subject>Lipid Metabolism</subject><subject>Liver - metabolism</subject><subject>Liver - pathology</subject><subject>Liver diseases</subject><subject>Male</subject><subject>MAP Kinase Kinase Kinases - metabolism</subject><subject>MAP Kinase Signaling System</subject><subject>Metabolic disorders</subject><subject>Mice, Transgenic</subject><subject>Nerve Tissue Proteins - metabolism</subject><subject>Phosphorylation</subject><subject>Steatosis</subject><subject>TAK1 protein</subject><subject>Transcription factors</subject><subject>Ubiquitin-protein ligase</subject><subject>Ubiquitination</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0T1vFDEQBmALgcgRKPgDyBINFJuMv-0yig6CEgmKo7a8e-PE0d7uYXuF8u9xcoECiYjKxTx6NZ6XkLcMThgAP73B_Qm3zrBnZMUUN50QCp6TFXADnWPCHZFXpdwCgJPcviRH3DjLNLgV8ZsbpGtBx3QdCtKa0z7kmirS3VxTpJbWkK-xFro5u2S0znSf5zZCmqayjGmiGUsqNUwD0jBtaakY6tw2Ci0lldfkRQxjwTeP7zH5_mm9Ob_orr5-_nJ-dtUNkknWhcCjtrLfRgkqCjH0DPrAzWC16FmUfZQGBEplFKAzg-A6RGsc9kGjYb04Jh8OuW29HwuW6nepDDiOYcJ5KZ618wijLGf_QRXXVnMrGn3_F72dlzy1j3jmQIDWzugnlbVOcemUbOrjQQ15LiVj9PucdiHfeQb-vkbfjuYfamz23WPi0u9w-0f-7q2B0wP4mUa8-3eSv1h_O0T-AknxpKw</recordid><startdate>201705</startdate><enddate>201705</enddate><creator>Yan, Feng‐Juan</creator><creator>Zhang, Xiao‐Jing</creator><creator>Wang, Wen‐Xin</creator><creator>Ji, Yan‐Xiao</creator><creator>Wang, Pi‐Xiao</creator><creator>Yang, Yang</creator><creator>Gong, Jun</creator><creator>Shen, Li‐Jun</creator><creator>Zhu, Xue‐Yong</creator><creator>Huang, Zan</creator><creator>Li, Hongliang</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201705</creationdate><title>The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis</title><author>Yan, Feng‐Juan ; Zhang, Xiao‐Jing ; Wang, Wen‐Xin ; Ji, Yan‐Xiao ; Wang, Pi‐Xiao ; Yang, Yang ; Gong, Jun ; Shen, Li‐Jun ; Zhu, Xue‐Yong ; Huang, Zan ; Li, Hongliang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4141-aa2f684bdf405f33cb10ba27c863b1f4bf4703e45750e97c326af879eba6e71b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>c-Jun protein</topic><topic>Carrier Proteins - metabolism</topic><topic>Clonal deletion</topic><topic>Diet, High-Fat</topic><topic>Fatty liver</topic><topic>Fatty Liver - enzymology</topic><topic>Fibrosis</topic><topic>Growth factors</topic><topic>Hepatocytes</topic><topic>Hepatology</topic><topic>High fat diet</topic><topic>Humans</topic><topic>Innate immunity</topic><topic>Insulin</topic><topic>Insulin Resistance</topic><topic>JNK protein</topic><topic>Lipid Metabolism</topic><topic>Liver - metabolism</topic><topic>Liver - pathology</topic><topic>Liver diseases</topic><topic>Male</topic><topic>MAP Kinase Kinase Kinases - metabolism</topic><topic>MAP Kinase Signaling System</topic><topic>Metabolic disorders</topic><topic>Mice, Transgenic</topic><topic>Nerve Tissue Proteins - metabolism</topic><topic>Phosphorylation</topic><topic>Steatosis</topic><topic>TAK1 protein</topic><topic>Transcription factors</topic><topic>Ubiquitin-protein ligase</topic><topic>Ubiquitination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yan, Feng‐Juan</creatorcontrib><creatorcontrib>Zhang, Xiao‐Jing</creatorcontrib><creatorcontrib>Wang, Wen‐Xin</creatorcontrib><creatorcontrib>Ji, Yan‐Xiao</creatorcontrib><creatorcontrib>Wang, Pi‐Xiao</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Gong, Jun</creatorcontrib><creatorcontrib>Shen, Li‐Jun</creatorcontrib><creatorcontrib>Zhu, Xue‐Yong</creatorcontrib><creatorcontrib>Huang, Zan</creatorcontrib><creatorcontrib>Li, Hongliang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yan, Feng‐Juan</au><au>Zhang, Xiao‐Jing</au><au>Wang, Wen‐Xin</au><au>Ji, Yan‐Xiao</au><au>Wang, Pi‐Xiao</au><au>Yang, Yang</au><au>Gong, Jun</au><au>Shen, Li‐Jun</au><au>Zhu, Xue‐Yong</au><au>Huang, Zan</au><au>Li, Hongliang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2017-05</date><risdate>2017</risdate><volume>65</volume><issue>5</issue><spage>1492</spage><epage>1511</epage><pages>1492-1511</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><coden>HPTLD9</coden><abstract>Tripartite motif 8 (TRIM8), an E3 ligase ubiquitously expressed in various cells, is closely involved in innate immunity. However, its role in nonalcoholic steatohepatitis is largely unknown. Here, we report evidence that TRIM8 is a robust enhancer of steatohepatitis and its complications induced by a high‐fat diet or a genetic deficiency (ob/ob). Using gain‐of‐function and loss‐of‐function approaches, we observed dramatic exacerbation of insulin resistance, hepatic steatosis, inflammation, and fibrosis by hepatocyte‐specific TRIM8 overexpression, whereas deletion or down‐regulation of TRIM8 in hepatocytes led to a completely opposite phenotype. Furthermore, investigations of the underlying mechanisms revealed that TRIM8 directly binds to and ubiquitinates transforming growth factor‐beta–activated kinase 1, thus promoting its phosphorylation and the activation of downstream c‐Jun N‐terminal kinase/p38 and nuclear factor κB signaling. Importantly, the participation of TRIM8 in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis was verified on the basis of its dramatically increased expression in the livers of these patients, suggesting a promising development of TRIM8 disturbance for the treatment of nonalcoholic steatohepatitis–related metabolic disorders. Conclusion: The E3 ligase TRIM8 is a potent regulator that exacerbates steatohepatitis and metabolic disorders dependent on its binding and ubiquitinating capacity on transforming growth factor‐beta–activated kinase 1. (Hepatology 2017;65:1492‐1511)</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>27981609</pmid><doi>10.1002/hep.28971</doi><tpages>20</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0270-9139
ispartof Hepatology (Baltimore, Md.), 2017-05, Vol.65 (5), p.1492-1511
issn 0270-9139
1527-3350
language eng
recordid cdi_proquest_miscellaneous_1897375821
source MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals
subjects Animals
c-Jun protein
Carrier Proteins - metabolism
Clonal deletion
Diet, High-Fat
Fatty liver
Fatty Liver - enzymology
Fibrosis
Growth factors
Hepatocytes
Hepatology
High fat diet
Humans
Innate immunity
Insulin
Insulin Resistance
JNK protein
Lipid Metabolism
Liver - metabolism
Liver - pathology
Liver diseases
Male
MAP Kinase Kinase Kinases - metabolism
MAP Kinase Signaling System
Metabolic disorders
Mice, Transgenic
Nerve Tissue Proteins - metabolism
Phosphorylation
Steatosis
TAK1 protein
Transcription factors
Ubiquitin-protein ligase
Ubiquitination
title The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T16%3A59%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20E3%20ligase%20tripartite%20motif%208%20targets%20TAK1%20to%20promote%20insulin%20resistance%20and%20steatohepatitis&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Yan,%20Feng%E2%80%90Juan&rft.date=2017-05&rft.volume=65&rft.issue=5&rft.spage=1492&rft.epage=1511&rft.pages=1492-1511&rft.issn=0270-9139&rft.eissn=1527-3350&rft.coden=HPTLD9&rft_id=info:doi/10.1002/hep.28971&rft_dat=%3Cproquest_cross%3E1897375821%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1889524954&rft_id=info:pmid/27981609&rfr_iscdi=true